We sought to determine if LACS1-3 also have this dual functionality. A yeast fat 1 Delta mutant is deficient in both LY2157299 research buy very-long-chain acyl-CoA synthetase activity and exogenous fatty acid uptake. We demonstrate that heterologous expression of LACS1, 2, or 3 is able to complement both of these deficiencies. Furthermore, expression of each LACS enzyme in yeast resulted in uptake of the long-chain fatty acid analogue, C-1-BODIPY-C-12. Only expression of LACS] resulted in uptake of the very-long-chain fatty acid analogue, BODIPY-C-16. These results demonstrate that LACS1, LACS2, and LACS3 have the dual functionality of yeast and mammalian FATP

enzymes. These findings have implications in the transmembrane transport and intracellular trafficking of plant lipids destined for export to the cuticle. (C) 2011 Elsevier Masson SAS. All rights reserved.”
“This paper presents a phonon transport model for bulk thermoelectric materials to investigate the effect of the grain sizes and grain shapes on phonon thermal conductivity. An analytical solution for the effective thermal conductivity contributing from the grains and grain boundaries of the bulk thermoelectric material is obtained, and the impact of the

grain geometric characteristics on the thermal conductivity is analyzed. The theoretical model exhibits quite a well description on the often experimentally observed grain size-dependent thermal conductivity. Meanwhile it is demonstrated that the grain shapes significantly influence the thermal conductivity, especially for small grain sizes (with buy CX-5461 dimensionless values xi(a) < 10). An optimal grain shape is achieved

that leads to a minimum value of thermal conductivity of the bulk thermoelectric material. (C) 2011 American Institute of Physics. [doi: URMC-099 solubility dmso 10.1063/1.3611421]“
“Background: Chronic granulomatous disease (CGD) is a rare inherited phagocytic disorder resulting in an increased susceptibility to infections including invasive fungal diseases (IFDs) and inflammatory complications. This study is aimed at assessing the incidence, prevalence, and outcome of IFDs among CGD patients followed in France.

Methods: CGD patients were identified through the French national registry for primary immunodeficiencies (PID) held by the French national reference Centre of PID (Centre de Reference Deficits Immunitaires Hereditaires), which comprises a total of 3083 patients including 155 with CGD followed between 1976 and 2008. A questionnaire was filled out for each episode of IFD. Information retrieved included a description of the IFD using the 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group IFD definition criteria.

Results: Of CGD patients, 42.6% (66/155) developed at least 1 episode of IFD. Overall incidence of IFD was 0.